Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexbudesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.73 |
| ▸ | PGR | P06401 | 4/20 | 0.73 |
| ▸ | AR | P10275 | 3/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.73 |
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.73 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | IL5 | P05113 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | MMP9 | P14780 | 1/20 | 0.73 |
| ▸ | THPO | P40225 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexbudesonide SCHEMBL4260550 | 1.00 | CYP3A4 (0.73) | CYP3A4NR3C1HIF1APGRAR | |
| Dexbudesonide SCHEMBL1302753 | 0.92 | NR3C1 (0.73) | CYP3A4NR3C1HIF1APGRAR | |
| Triamcinolone Acetonide SCHEMBL9987506 | 0.91 | CYP3A4 (0.75) | CYP3A4NR3C1HIF1APGRAR | |
| Desonide SCHEMBL11778722 | 0.89 | CYP3A4 (0.73) | CYP3A4NR3C1HIF1APGRAR | |
| Dexbudesonide SCHEMBL8423471 | 0.89 | NR3C1 (0.70) | CYP3A4NR3C1HIF1APGRAR | |
| SCHEMBL10337827 | 0.86 | CYP3A4 (0.73) | CYP3A4NR3C1HIF1APGRAR | |
| SCHEMBL7134775 | 0.86 | CYP3A4 (0.73) | CYP3A4NR3C1HIF1APGRAR | |
| SCHEMBL7741442 | 0.86 | CYP3A4 (0.73) | CYP3A4NR3C1HIF1APGRAR | |
| Budesonide SCHEMBL1130417 | 0.86 | NR3C1 (1.00) | CYP3A4NR3C1HIF1APGRAR | |
| Budesonide SCHEMBL13871728 | 0.86 | NR3C1 (1.00) | CYP3A4NR3C1HIF1APGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3676402-B1 | A METHOD TO MONITOR PHARMACODYNAMIC RESPONSES MEDIATED BY IN VIVO ADMINISTRATION OF GLUCOCORTICOIDS | BRISTOL MYERS SQUIBB CO (US) | 2023-12-27 | — | — | EP | claimed |
| US-11696890-B2 | Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity | HK PHARMA (US) | 2023-07-11 | — | — | US | claimed |
| US-20200299770-A1 | A METHOD TO MONITOR PHARMACODYNAMIC RESPONSES MEDIATED BY IN VIVO ADMINISTRATION OF GLUCOCORTICOIDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-24 | — | — | US | claimed |
| EP-3676402-A1 | A METHOD TO MONITOR PHARMACODYNAMIC RESPONSES MEDIATED BY IN VIVO ADMINISTRATION OF GLUCOCORTICOIDS | Bristol-Myers Squibb Company (US) | 2020-07-08 | — | — | EP | claimed |
| CN-111051534-A | Method for monitoring pharmacodynamic response mediated by glucocorticoid administration in vivo | 百时美施贵宝公司 | 2020-04-21 | — | — | CN | claimed |
| WO-2019046233-A1 | A METHOD TO MONITOR PHARMACODYNAMIC RESPONSES MEDIATED BY IN VIVO ADMINISTRATION OF GLUCOCORTICOIDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-03-07 | — | — | WO | claimed |
| WO-2024097415-A1 | TUMESCENT SOLUTION WITH B VITAMINS | HK TUMESCENT PHARMA (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240148776-A1 | TUMESCENT SOLUTION WITH B VITAMINS | HK TUMESCENT PHARMA | 2024-05-09 | — | — | US | disclosed |
| EP-3676402-B1 | A METHOD TO MONITOR PHARMACODYNAMIC RESPONSES MEDIATED BY IN VIVO ADMINISTRATION OF GLUCOCORTICOIDS | BRISTOL MYERS SQUIBB CO (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11723859-B2 | Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity | HK PHARMA (US) | 2023-08-15 | — | — | US | disclosed |
| US-11696890-B2 | Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity | HK PHARMA (US) | 2023-07-11 | — | — | US | disclosed |
| US-20220175665-A1 | TUMESCENT INFILTRATION DRUG DELIVERY OF HIGH SUBCUTANEOUS DRUG CONCENTRATIONS WITH PROLONGED LOCAL AND SYSTEMIC EFFECTS AND MINIMAL LOCAL OR SYSTEMIC TOXICITY | HK TUMESCENT PHARMA | 2022-06-09 | — | — | US | disclosed |
| US-20220175664-A1 | TUMESCENT INFILTRATION DRUG DELIVERY OF HIGH SUBCUTANEOUS DRUG CONCENTRATIONS WITH PROLONGED LOCAL AND SYSTEMIC EFFECTS AND MINIMAL LOCAL OR SYSTEMIC TOXICITY | HK TUMESCENT PHARMA | 2022-06-09 | — | — | US | disclosed |
| WO-2020160328-A1 | TUMESCENT INFILTRATION DRUG DELIVERY OF CANNABINOIDS | HK PHARMA (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-3676402-A1 | A METHOD TO MONITOR PHARMACODYNAMIC RESPONSES MEDIATED BY IN VIVO ADMINISTRATION OF GLUCOCORTICOIDS | Bristol-Myers Squibb Company (US) | 2020-07-08 | — | — | EP | disclosed |
| CN-111051534-A | Method for monitoring pharmacodynamic response mediated by glucocorticoid administration in vivo | 百时美施贵宝公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20200101012-A1 | TUMESCENT INFILTRATION DRUG DELIVERY OF HIGH SUBCUTANEOUS DRUG CONCENTRATIONS WITH PROLONGED LOCAL AND SYSTEMIC EFFECTS AND MINIMAL LOCAL OR SYSTEMIC TOXICITY | HK TUMESCENT PHARMA | 2020-04-02 | — | — | US | disclosed |
| US-20190240189-A1 | TUMESCENT INFILTRATION DRUG DELIVERY OF CANNABINOIDS | HK TUMESCENT PHARMA | 2019-08-08 | — | — | US | disclosed |
| WO-2019046233-A1 | A METHOD TO MONITOR PHARMACODYNAMIC RESPONSES MEDIATED BY IN VIVO ADMINISTRATION OF GLUCOCORTICOIDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20170100331-A1 | TUMESCENT INFILTRATION DRUG DELIVERY OF HIGH SUBCUTANEOUS DRUG CONCENTRATIONS WITH PROLONGED LOCAL AND SYSTEMIC EFFECTS AND MINIMAL LOCAL OR SYSTEMIC TOXICITY | HK TUMESCENT PHARMA | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240189-A1 | TUMESCENT INFILTRATION DRUG DELIVERY OF CANNABINOIDS | CNR1, CNR2, OPRM1 | NR3C1 993/4885CYP3A4 1292/4885HIF1A 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.